Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pelthos Therapeutics ( (PTHS) ) just unveiled an announcement.
On September 2, 2025, Pelthos Therapeutics announced that its CEO and CFO would present at the Wells Fargo 2025 Healthcare Conference, providing updates on their product pipeline and recent business developments, including the commercial launch of Zelsuvmi. This presentation highlights Pelthos’ strategic efforts to strengthen its market position and engage stakeholders by showcasing its innovative solutions in the healthcare industry.
The most recent analyst rating on (PTHS) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
More about Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company focused on commercializing innovative therapeutic products, with a recent launch of Zelsuvmi, the first at-home treatment for Molluscum contagiosum, a contagious viral disease affecting millions. The company aims to address unmet treatment needs in a large market, with a total addressable market worth over $20 billion.
Average Trading Volume: 62,268
Technical Sentiment Signal: Strong Buy
For an in-depth examination of PTHS stock, go to TipRanks’ Overview page.